Catalog No.
PHH72401
Species reactivity
Human
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human TIGIT (Met22-Pro141).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
VSTM3,TIGIT,V-set and transmembrane domain-containing protein 3,VSIG9,V-set and immunoglobulin domain-containing protein 9,T-cell immunoreceptor with Ig and ITIM domains
Purification
Purified by antigen affinity column.
Accession
Q495A1
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. PMID: 19815499
TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer. PMID: 33224630
TIGIT and PD-1 may serve as potential prognostic biomarkers for gastric cancer. PMID: 32122675
TIGIT enhances CD4(+) regulatory T-cell response and mediates immune suppression in a murine ovarian cancer model. PMID: 32212317
TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer. PMID: 32665122
Higher TIGIT(+)CD226(-) gammadelta T cells in Patients with Acute Myeloid Leukemia. PMID: 32819181
Treatment of murine lupus with TIGIT-Ig. PMID: 31005675
TIGIT Blockade and IL15 in Tumor Immunotherapy: Together is Better. PMID: 32817077
PD-1(+) TIGIT(+) CD8(+) T cells are associated with pathogenesis and progression of patients with hepatitis B virus-related hepatocellular carcinoma. PMID: 31720814
TIGIT presents earlier expression dynamic than PD-1 in activated CD8(+) T cells and is upregulated in non-small cell lung cancer patients. PMID: 32890458
Immunotherapy of multiple myeloma. PMID: 32149732
Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. PMID: 25680274
TIGIT-Ig shows therapeutic potential in SLE. PMID: 31048781
TIGIT, A Novel Therapeutic Target for Tumor Immunotherapy. PMID: 27819527
TIGIT signaling restores suppressor function of Th1 Tregs. PMID: 30728325
Alteration of CD226/TIGIT immune checkpoint on T cells in the pathogenesis of primary Sjogren's syndrome. PMID: 32466852
DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer. PMID: 29983831
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. PMID: 31690319
TOX-expressing terminally exhausted tumor-infiltrating CD8(+) T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer. PMID: 33249194
NK Cell-Based Immune Checkpoint Inhibition. PMID: 32117298
For research use only. Not for human or drug use.
